bleak. The papers we publish this week aim to show why withdrawing from multilateralism would be the wrong response to Ebola. It is perfectly understandable why many nations view threats to their citizens and sovereignty as reasons to act alone, on the basis of a narrow concept of strengthened state security. But human beings have many affi liations and interests. We are not defi ned only as citizens of a single nationstate. To reach a fuller and richer understanding of health security, governments, development agencies, and health organisations might also argue that each of us has an affi liation to the larger world we inhabit-a global identity that demands global solutions through cooperation between nations. Global health security, we think, is an idea that presses the case in favour of a renaissance in multilateralism, not its demise.
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The Lancet, London EC2Y 5AS, UK Oestrogen-progestagen sales decreased precipitously in the following year. Additional analyses from the trial showed increased risk of myocardial infarction restricted to women who used oestrogen-progestagen beyond menopause; furthermore, several adverse eff ects increased with hormone therapy use after menopause in extended follow-up. 4 Currently recommended indications for hormone therapy use are restricted to treatment of menopausal symptoms, not for prevention of chronic disease. 5 Regulatory decisions and public health recommendations related to hormone therapy use were based mostly on fi ndings from the Women's Health Initiative trial. However, reliance on one trial alone has limitations; this trial was not powered to assess rare endpoints such as ovarian cancer, and, furthermore, the trial was mainly designed to assess short-term use and short-term health eff ects. Since early 2000, fi ndings from observational studies have suggested that long-duration hormone therapy use is associated with ovarian cancer risk. 6 In The Lancet, the Collaborative Group on Epidemiological Studies of Ovarian Cancer 7 reports fi ndings from a meta-analysis of individual participant data from 52 epidemiological studies assessing hormone therapy use and ovarian cancer risk. The principal analyses involved data from 17 prospective studies. These fi ndings support the addition of ovarian cancer to the list of adverse eff ects associated with hormone therapy use. However, compared with cardiovascular diseases and breast cancer, ovarian cancer is far less common, suggesting that overall risk assessment of hormone therapy will not be strongly aff ected by these results. Since the announcement of the Women's Health Initiative fi ndings, the use of hormone therapy has dropped substantially, and in the USA use of low-dose regimens is more prevalent than use of standard-dose and high-dose regimens. 8 The present study did not evaluate dose, and median year of diagnosis was 2001 for the cohort studies-slightly before the widespread change in use patterns occurred. In view of recommendations to use the lowest dose possible for the shortest duration, the study fi ndings did show signifi cant increases in ovarian cancer risk even among current short-term users (median duration 3 years), but a few years after stopping short-term use (after, however, a median of only 1 year of use) the risks were no longer increased. It is unclear to what extent the diff erences in median duration of use between current and previous users are responsible for these disparate fi ndings. Further, it remains to be explored to what extent risk is reduced for low-dose regimens and nonoral formulations.
Assessment of the association between hormone use and women's cancers can provide important insights into hormone-driven carcinogenesis. Importantly, oestrogen-progestagen reduced endometrial cancer risk compared with oestrogen alone, whereas risk was unchanged for ovarian cancer, and much higher for breast cancer, [9] [10] [11] suggesting that progestagen has tumour-promoting eff ects in the breast but mitigates tumour-promoting eff ects of oestrogen on the endometrium. The almost immediate decrease in incidence of breast and ovarian cancer after announcement of the Women's Health Initiative results and subsequent fall in oestrogen-progestagen use 12 supports an important role of hormone therapy in the late stages of carcinogenesis. The results from the accompanying study 7 are consistent with this notion, because ovarian cancer risk fell almost to baseline about 5 years after cessation of short-duration use (although some increased risk remained more than 5 years after discontinuation of lengthy use).
At all three cancer sites, hormone use showed subtype-specifi c associations with cancer risk, underlining the need for well-powered, subtype-specifi c studies of hormone therapy use. Importantly, hormone therapy use was associated with only serous and endometrioid ovarian cancers. With the exception of the inverse association with oral contraceptive use, very few risk factors have emerged for serous ovarian cancer, the most common and most lethal subtype; therefore, any reduction in risk, for example by avoidance of hormone therapy use, could lead to relevant reductions in ovarian cancer mortality.
The available data for breast cancer and cardiovascular outcomes from clinical trials and observational data dictate caution in the use of hormone therapy. In the context of the observational data presented in this study, 7 it is still not clear whether the current recommendation to use hormone therapy for the shortest duration possible is appropriate for women who are concerned about an increased risk of ovarian cancer. The current report underlines the importance and limitations of observational The aim of palliative therapy in oncology is to prolong life and maintain quality of life for patients, with the least therapy necessary to control disease. The improvement in overall survival seen in metastatic colorectal cancer over the past decade is intrinsically associated with the increased number of active drugs in the management of disease, and a better understanding of how best to use these drugs. 1 The availability of improved supportive care, less toxic regimens, and targeted drugs have led to a shift in the treatment paradigm. Previously, oncologists commonly used a fi xed number of initial chemotherapy cycles or treatment to best response, followed by a complete treatment-free interval. Now, the emphasis has shifted toward prolonged duration of therapy to control cancer growth in the longer term.
However, one of the most commonly used treatments in the fi rst-line setting in metastatic colorectal cancer, a combination of oxaliplatin and fl uoropyrimidine, does not lend itself to prolonged treatment because of cumulative neurotoxic eff ects of oxaliplatin. Results from trials with an oxaliplatin-based therapy have consistently shown that more patients come off therapy because of toxic eff ects than because of progressive disease. 2, 3 This issue is accentuated when a drug such as bevacizumab is added, which can further prolong time to tumour progression.
Findings from a detailed analysis of one of the largest trials of fi rst-line therapy with a combination of bevacizumab, fl uoropyrimidine, and oxaliplatin in metastatic colorectal cancer showed that patients who received treatment until tumour progression obtained the greatest benefi t of anti-VEGF treatment with bevacizumab. 3 Additionally, fi ndings from several phase 3 studies have confi rmed that prolonged duration of anti-VEGF treatment, even beyond RECIST-defi ned tumour progression, is associated with improved outcomes in metastatic colorectal cancer. 4, 5 Thus, if an oxaliplatin-based fi rst-line therapy is used, and one emphasis of fi rst-line therapy is to optimise and maximise duration of treatment to provide prolonged tumour control, a strategy has to be developed to pre-emptively deal with the issue of oxaliplatin's cumulative neurotoxic eff ects.
Several trials have investigated the role of maintenance therapy in metastatic colorectal When less is more: maintenance therapy in colorectal cancer data for rare and long-term outcomes, especially for the complex associations between regimen, dose, duration, route of administration, and timing of hormone therapy use with ovarian, breast, and endometrial cancers. 
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